[Form 4] Helix Acquisition Corp. II Insider Trading Activity

Rhea-AI Filing Summary

Mehra Uneek, Chief Financial Officer and director of BridgeBio Oncology Therapeutics, Inc. (ticker BBOT), reported the acquisition of 633,570 stock options on 08/26/2025. The options have an exercise price of $9.59 and are held directly by the reporting person, leaving 633,570 options beneficially owned following the transaction. The filing is signed by an attorney-in-fact on 08/28/2025. Under the grant terms, 25% of the underlying shares vest on July 21, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to continued service. The instrument is a standard stock option intended to align executive compensation with shareholder value.

Positive

• Grant aligns CFO incentives with shareholders through long-term vesting
• Prompt disclosure of the option grant and vesting schedule under Section 16

Negative

• Potential dilution from 633,570 options if exercised, with no outstanding share count provided
• No performance-based vesting specified; vesting is service-based which may be less directly tied to shareholder returns

Insights

Financial Analyst

TL;DR: A sizable option grant to the CFO ties compensation to long-term share performance but increases potential share dilution.

The grant of 633,570 options at a $9.59 exercise price is a material compensation event for a senior officer and reflects a retention and performance incentive structure given the multi-year vesting schedule. For investors, the key considerations are the option strike relative to current share price, the potential dilution if exercised, and how this aligns executive incentives with long-term value creation. This disclosure does not provide current outstanding share count or immediate cash impact; therefore, precise dilution and financial effects cannot be calculated from this filing alone.

Compensation / Corporate Governance Specialist

TL;DR: Vesting schedule and sizable award are consistent with retention-focused executive pay; governance transparency is adequate.

The filing clearly states vesting—25% after roughly one year then monthly over three years—demonstrating a standard service-based retention design. The direct ownership is disclosed and the grant is reported promptly, satisfying Section 16 reporting obligations. Missing from the filing are any performance-based vesting conditions or the total option pool context; without that, assessing whether the award is dilutive relative to shareholder interests is limited.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mehra Uneek

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$9.59	08/26/2025		A		633,570		(1)	08/25/2035	Common Stock	633,570	$0	633,570	D

Explanation of Responses:

1. 25% of the shares underlying such option shall vest on July 21, 2026, with the remainder vesting in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service the Issuer on each such vesting date.

	/s/ Aaron Chan, Attorney-in-Fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 and what is their role at BBOT?

The reporting person is Mehra Uneek, who is identified as Chief Financial Officer and a director of BridgeBio Oncology Therapeutics, Inc.

What was acquired according to the Form 4 for BBOT?

The Form 4 reports acquisition of 633,570 stock options (a right to buy common stock) on 08/26/2025.

What is the exercise price and vesting schedule of the options?

The options have an exercise price of $9.59. 25% vest on July 21, 2026, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to continuous service.

How many options does the reporting person beneficially own after the transaction?

The filing shows the reporting person beneficially owns 633,570 options following the reported transaction.

When was the Form 4 signed?

The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 08/28/2025.